Drug profile · INN
elacestrant
ORSERDU
elacestrant (ORSERDU) is a estrogen receptor alpha degrader.
EMA: approved Antineoplastic and immunomodulating agents (L02) L02BA
Patents linked 0
Pipeline programs 10
News articles 0
Drug details — elacestrant
- Class
- Antineoplastic and immunomodulating agents (L02)
- Route
- —
- Patents
- 0
- Programs
- 10
- Data quality
- 0.83
Quick answer
elacestrant (ORSERDU) is a estrogen receptor alpha degrader.
Key facts
INN elacestrant
Brand ORSERDU
Mechanism Estrogen receptor alpha degrader
Target Estrogen receptor
Therapeutic class Antineoplastic and immunomodulating agents (L02)
ATC code L02BA
Mechanism of action
Estrogen receptor alpha degrader
Primary target: Estrogen receptor
Approval history
| Authority | Status | Date |
|---|---|---|
| EMA | approved | — |
Pipeline programs
Related & competitor drugs
Frequently asked questions
What is elacestrant?
elacestrant (ORSERDU) is a estrogen receptor alpha degrader.
What is the brand name for elacestrant?
ORSERDU is a marketed brand name for elacestrant. Check FDA Drugs@FDA for the current US label holder and prescribing information.